Blueprint Medicines
149 articles about Blueprint Medicines
-
Blueprint Medicines, Opiant Pharmaceuticals and Lexicon Pharmaceuticals are all awaiting FDA decisions this week. -
Blueprint Medicines Reports First Quarter 2023 Results
5/4/2023
Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the first quarter ended March 31, 2023.
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 04, 2023
5/4/2023
Blueprint Medicines Corporation announced that, effective May 1, 2023, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 18,300 shares of its common stock and an aggregate of 9,146 restricted stock units to eleven new employees under Blueprint Medicines' 2020 Inducement Plan.
-
Blueprint Medicines to Present New Clinical Data Across Broad Precision Therapy Pipeline at 2023 ASCO Annual Meeting
4/26/2023
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the acceptance of clinical abstracts for multiple programs across its precision therapy portfolio at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2 to 6.
-
Blueprint Medicines to Present at Upcoming Investor Conferences - April 11, 2023
4/11/2023
Blueprint Medicines Corporation (Nasdaq: BPMC) today announced its participation in the following upcoming investor conferences.
-
Blueprint Medicines Presents Registrational Data from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting
2/26/2023
Blueprint Medicines Corporation announced detailed results from the PIONEER trial of AYVAKIT® in patients with indolent systemic mastocytosis.
-
Blueprint Medicines to Regain Global Rights to GAVRETO® (pralsetinib) from Roche
2/23/2023
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced it will regain global commercialization and development rights to GAVRETO® (pralsetinib), excluding Greater China , following a decision by Roche to discontinue the collaboration agreement between the companies for GAVRETO for strategic reasons.
-
Blueprint Medicines Announces Partial Clinical Hold for Phase 1/2 VELA Trial of BLU-222
2/10/2023
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) verbally informed the company on February 8, 2023 that it has placed a partial clinical hold on the Phase 1/2 VELA trial of BLU-222 due to visual adverse events (AEs) observed in a limited number of patients.
-
Blueprint Medicines to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
2/9/2023
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 16, 2023 to report its fourth quarter and full year 2022 financial results and provide a corporate update.
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 07, 2023
2/7/2023
Blueprint Medicines Corporation announced that, effective February 1, 2023, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 36,260 shares of its common stock and an aggregate of 18,119 restricted stock units to 24 new employees under Blueprint Medicines' 2020 Inducement Plan.
-
Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis
1/23/2023
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental new drug application for AYVAKIT ® (avapritinib) for the treatment of adults with indolent systemic mastocytosis (SM)
-
Blueprint Medicines Provides 2023 Portfolio Goals to Achieve Precision at Scale
1/5/2023
Blueprint Medicines Corporation outlined upcoming portfolio milestones advancing the company's 2027 Blueprint to achieve Precision at Scale, a five-year growth strategy to reach broad patient populations by leveraging its scientific leadership, proven development capability and integrated business infrastructure.
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 04, 2023
1/4/2023
Blueprint Medicines Corporation announced that, effective January 1, 2023, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 6,887 shares of its common stock and an aggregate of 3,443 restricted stock units to five new employees under Blueprint Medicines' 2020 Inducement Plan.
-
Blueprint Medicines Reports Clinical Data Highlighting Leadership in Developing Targeted Treatment Options for Patients with Systemic Mastocytosis
12/11/2022
Blueprint Medicines Corporation announced AYVAKIT® data showing high, durable response rates and prolonged overall survival in patients with advanced systemic mastocytosis, including SM with an associated hematological neoplasm.
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 05, 2022
12/5/2022
Blueprint Medicines Corporation announced that, effective December 1, 2022, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 23,604 shares of its common stock and an aggregate of 11,800 restricted stock units to sixteen new employees under Blueprint Medicines' 2020 Inducement Plan.
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 04, 2022
11/4/2022
Blueprint Medicines Corporation announced that, effective November 1, 2022, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 15,656 shares of its common stock and an aggregate of 7,824 restricted stock units to fourteen new employees under Blueprint Medicines' 2020 Inducement Plan.
-
Blueprint Medicines Outlines 2027 Blueprint to Achieve Precision Medicine at Scale and Reports Third Quarter 2022 Financial Results at Investor Day 2022
11/1/2022
Blueprint Medicines (NASDAQ: BPMC) today announced its 2027 Blueprint to achieve precision medicine at scale, a five-year business strategy to expand the company's reach to broader patient populations by leveraging its scientific leadership, proven development capability and integrated business.
-
Blueprint Medicines to Host Investor Day and Announce Third Quarter 2022 Financial Results on November 1, 2022
10/19/2022
Blueprint Medicines Corporation today announced that it will host an Investor Day for analysts and investors on Tuesday, November 1, 2022 beginning at 8:30 a.m. ET in New York City.
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 06, 2022
10/6/2022
Blueprint Medicines Corporation announced that, effective October 1, 2022, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 11,381 shares of its common stock and an aggregate of 5,688 restricted stock units to eight new employees under Blueprint Medicines' 2020 Inducement Plan.
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 06, 2022
9/6/2022
Blueprint Medicines Corporation announced that, effective September 1, 2022, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 18,170 shares of its common stock and an aggregate of 9,083 restricted stock units to thirteen new employees under Blueprint Medicines' 2020 Inducement Plan.